MERIDIAN BIOSCIENCE INC

Delisted

CIK 794172fmd_1JHN5GNR21H1YDE1DQYCKVB3K2Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Oct 01, 2007 to Dec 31, 2022, 56 periods

Income Statement · Annual · Millions · USD
Line item	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
Total revenues	189	189	195	196	201	214	201	254	318	333
Cost of revenue	68	72	73	69	76	83	82	97	117	145
Gross profit	121	117	122	127	124	131	119	156	201	188
Research and development	11	13	13	14	16	17	18	24	24	24
Selling, general and administrative	53	52	53	59	63	70	62	71	76	88
Total operating expenses	64	65	66	76	87	99	86	95	108	134
Operating income	57	52	56	51	37	32	33	61	93	54
Interest expense	–	–	–	1	2	2	2	3	2	1
Interest and investment income	0	0	0	0	0	0	1	0	0	0
Other non-operating income (expense)	0	(0)	(1)	(1)	(1)	(1)	(1)	(2)	(3)	(0)
Income before taxes	57	52	55	51	36	30	32	59	90	54
Income tax expense	19	17	20	18	15	7	7	13	19	12
Net income from continuing operations	38	35	36	32	22	24	24	46	71	42
Net income	38	35	36	32	22	24	24	46	71	42